CEOInterviews.AI
Start App
Try: AI strategy tariffs earnings guidance layoffs interest rates growth

Randy Teel

President and Chief Executive Officer, Arvinas

Search every verified Randy Teel interview, podcast appearance, and on-the-record quote — each transcript cross-checked by AI and human review to confirm speaker identity. Randy Teel, President and CEO of Arvinas, discussed the company’s strategic pivot to an early-stage pipeline following the outlicensing of its lead asset, Vepdegestrant (VEP), in recent podcast appearances. He described the decision to publicly announce the search for a new partner for VEP as one of the most difficult but valuable moves the company made, noting that it aligned internal and external messaging and allowed Arvinas to focus on its phase one programs, including the BCL6 degrader ARV-393. Teel characterized outlicensing not as a setback but as a function of having a platform technology applicable to many disease-causing proteins. Teel also reflected on his tenure at Arvinas since joining in 2018 as Vice President of Corporate Development and his progression to CEO. He emphasized the challenges of capital allocation for platform companies and the need to balance platform progress with clinical focus, citing earlier programs like a BET degrader that preceded the company’s current pipeline. He stated that Arvinas’s best days are ahead as it moves its core phase one assets through important data updates over the next couple of years.

Recent appearances

  • Life after the lead asset: Advancing an early-stage pipeline

    July 30, 2026 · 📺 BioSpace

    In this episode of Denatured presented by Arvinas, Jennifer Smith-Parker speaks to Arvinas President and CEO Randy Teel about the strategic discipline and leadership required to successfully refocus a company on an early-stage pipeline after a lead asset is outlicensed, discontinued or otherwise falls away — an inflection point many biotech and pharma companies face, but few navigate effectively. This episode is presented in partnership with https://www.arvinas.com/. Host   / jennifersmithparker  , Director of Insights, BioSpace Guest   / randyteel  , President and CEO, Arvinas

    Watch on YouTube ↗

  • Episode 184 - Randy Teel - President & CEO Arvinas

    June 04, 2026 · 📺 The Biohub

    In this episode of The BioHub Podcast, Max sits down with Randy Teel, President and CEO of Arvinas. Randy joined Arvinas in 2018 as Vice President of Corporate Development and has since helped guide the company through a period of significant growth, ultimately stepping into the CEO role. Today, Arvinas is one of the pioneers in targeted protein degradation, using its PROTAC platform to develop therapies designed to eliminate disease-causing proteins. In this conversation, we discuss Randy’s journey from strategy and corporate development into the CEO seat, the evolution of Arvinas from an…

    Watch on YouTube ↗

The summary and quote tags on this profile are produced with AI assistance from verified, first-person interview transcripts, then checked by our team to confirm the speaker's identity and the accuracy of every quote. See how we verify →